Efferocytosis Inhibition in MSCs for Bone Loss Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bone loss and osteoporosis are inadequate, leading to significant medical issues such as decreased bone density and increased fragility, particularly affecting women and aging populations.

Innovation Solution

Administering agents that inhibit efferocytosis by mesenchymal stromal cells (MSCs), such as TAM receptor kinase inhibitors, to reduce bone resorption and increase bone density.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for bone loss and osteoporosis are used, then some therapeutic effect is achieved, but the treatment is inadequate and does not sufficiently increase bone density or prevent bone loss

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidbone density increase rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the therapeutic parameter from conventional bone-targeted treatments to efferocytosis inhibition. By targeting the TAM receptor kinase pathway and inhibiting efferocytosis in MSCs, the treatment achieves a 10-15% increase in bone density, representing a significant parameter change in therapeutic efficacy compared to conventional treatments.

Inventive Principle:

Principle #35Parameter changes

2Strength

If efferocytosis by mesenchymal stromal cells is inhibited, then bone density increases and bone loss is reduced, but this represents a novel mechanism different from conventional treatments

Engineering Contradiction:

Improvebone densityVSAvoidtreatment mechanism complexity

Core Design Contradiction:

StrengthVSDevice complexity

Solution Approach 1:

The patent introduces TAM receptor kinase inhibitors as intermediary agents that mediate between the administered compound and the efferocytosis process. These inhibitors specifically block the TAM receptor signaling pathway in MSCs, thereby reducing efferocytosis and preventing bone loss without directly affecting bone tissue.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Strength

If a more effective treatment for preventing bone loss is developed, then bone density and strength are improved, but this addresses the unmet need in current osteoporosis therapy

Engineering Contradiction:

Improvebone strengthVSAvoidcurrent treatment adequacy

Core Design Contradiction:

StrengthVSReliability

Solution Approach 1:

The patent extracts and inhibits the specific pathological process of efferocytosis in MSCs from the overall bone remodeling process. By using TAM receptor kinase inhibitors to selectively block this harmful efferocytosis activity, the treatment prevents bone loss while maintaining normal bone physiology, achieving 10-15% bone density increase.

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method results in a 10-15% increase in bone density and reduction in bone loss in both young and aged individuals, effectively treating conditions associated with reduced bone density.

Implementation Method 1

agents capable of reducing efferocytosis by mesenchymal stromal cells (MSCs), such as TAM receptor kinase inhibitors

Methodology Applied

Scientific EffectEfferocytosis:

Implementation Method 2

reduce bone resorption and increase bone density

Methodology Applied

Scientific EffectBone resorption:

Data Source

PatentUS20260069610A1Inhibition of efferocytosis as a treatment to prevent bone loss and increase bone density and strength

Publication Date: 2026.03.12 UNIVERSITY OF ROCHESTER

AI summary

This disclosure relates methods and compositions for preventing bone loss and increasing bone density and strength.